Drug Trial Radar · NCT00436553
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Last checked: Nov 19, 2026Latest source record: Apr 19, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
321
Actual
Start
Feb 2007
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.
Conditions
- Macular Degeneration
- Choroidal Neovascularization
Interventions
Verteporfin Photodynamic TherapyDrug
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
RanibizumabDrug
Ranibizumab 0.5 mg administered as an intravitreal injection.
Verteporfin PlaceboDrug
To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Ranibizumab PlaceboDrug
To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12Time frame: Baseline and Month 12
- Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 VisitTime frame: Month 2 up to Month 11
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Pasadena, California
Novartis Investigative Site
Sacramento, California
West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130
San Francisco, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Denver, Colorado
Novartis Investigative Site
‘Aiea, Hawaii
Novartis Investigative Site
Iowa City, Iowa
Novartis Investigative Site
Wichita, Kansas
Novartis Investigative Site
Lexington, Kentucky
Novartis Investigative Site
Paducah, Kentucky
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Grand Rapids, Michigan
Novartis Investigative SIte
Royal Oak, Michigan
Novartis Investigative Site
Williamsburg, Michigan
Novartis Investigative Site
Independence, Missouri
Novartis Investigative Site
St Louis, Missouri
Novartis Investigative Site
Toms River, New Jersey
Novartis Investigative Site
Lynbrook, New York
Novartis Investigative Site
Rochester, New York
Novartis Investigative Site
Beachwood, Ohio
Novartis Investigative Site
Cincinnati, Ohio
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
West Mifflin, Pennsylvania
Novartis Investigative Site
West Columbia, South Carolina
Novartis Investigative Site
Rapid City, South Dakota
Novartis Investigative Site
Kingsport, Tennessee
Novartis Investigative Site
Knoxville, Tennessee
Novartis Investigative Site
Austin, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Fairfax, Virginia
Novartis Investigative Site
Richmond, Virginia
Novartis Investigative Site
Milwaukee, Wisconsin
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Halifax, Nova Scotia, Canada
Ivey Eye Institute, Dr. Thomas Sheidow
London, Ontario, Canada
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.